International Journal of Surgical Oncology最新文献

{"title":"Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma.","authors":"Manuel Díez-Alonso,&nbsp;Fernando Mendoza-Moreno,&nbsp;Remedios Gómez-Sanz,&nbsp;Belén Matías-García,&nbsp;Enrique Ovejero-Merino,&nbsp;Raquel Molina,&nbsp;Sonia Soto-Schütte,&nbsp;Alberto San Juan,&nbsp;Alberto Gutierrez-Calvo","doi":"10.1155/2021/3946875","DOIUrl":"https://doi.org/10.1155/2021/3946875","url":null,"abstract":"<p><strong>Objective: </strong>The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM).</p><p><strong>Materials and methods: </strong>A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression.</p><p><strong>Results: </strong>A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan-Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) (<i>P</i>=0.001). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1-10 was 71% and with PCI 11-20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively (<i>P</i>=0.025). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342-3.424).</p><p><strong>Conclusion: </strong>The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"3946875"},"PeriodicalIF":1.5,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39443833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal Stromal Tumor (GIST) and Synchronous Intra-Abdominal Liposarcoma: A Report of Two Rare Cases and Literature Review.","authors":"Alexandros Diamantis,&nbsp;Athina A Samara,&nbsp;Ioannis Baloyiannis,&nbsp;Dimitrios Symeonidis,&nbsp;Andreas-Marios Diamantis,&nbsp;Maria Tolia,&nbsp;Konstantinos Bouliaris,&nbsp;Georgios Koukoulis,&nbsp;Konstantinos Tepetes","doi":"10.1155/2021/2626635","DOIUrl":"https://doi.org/10.1155/2021/2626635","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrointestinal stromal tumors (GISTs) quite frequently occur synchronously with other malignancies, with most cases being adenocarcinomas. GISTs and liposarcomas are both of mesenchymal origin, and their coexistence is extremely rare.</p><p><strong>Methods: </strong>We conducted a review of the current literature regarding the synchronous occurrence of GISTs and intra-abdominal liposarcomas. An electronic search of the literature was undertaken using MEDLINE (database provider PubMed). Furthermore, we present the first described case of an 86-year-old male with a GIST and synchronous liposarcoma, both located in the stomach, as well as a 66-year-old male with a gastric GIST and concurrent retroperitoneal liposarcoma.</p><p><strong>Results: </strong>A total of 5 cases of synchronous GIST and intra-abdominal liposarcoma have been reported in the literature to date, with the most recent cases included in the present study.</p><p><strong>Conclusion: </strong>Further research is required to explain any possible correlation in the coexistence of these different neoplasms of the same origin. Meanwhile, R0 resection of both tumors remains the treatment of choice.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"2626635"},"PeriodicalIF":1.5,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39416375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer.","authors":"Lauri Laru,&nbsp;Hanna Ronkainen,&nbsp;Markku H Vaarala","doi":"10.1155/2021/5237695","DOIUrl":"https://doi.org/10.1155/2021/5237695","url":null,"abstract":"<p><p>Since the introduction of targeted therapies (TTs) for metastatic renal cell cancer (mRCC) in 2005, a limited amount of epidemiological data on efficacy of modern drug therapies for synchronous mRCC has been published. We present a comprehensive nationwide cohort including all cases of primarily metastasized renal cell cancer among adults diagnosed between 2005 and 2010, based on data from the Finnish Cancer Registry and patient records from treating hospitals. Applied treatment protocols and survival outcomes were analyzed. A total of 977 patients were included in the analysis; 499 patients were diagnosed between 2005 and 2007 and 478 patients were diagnosed between 2008 and 2010. The median overall survival (OS) was 8.80 months (95% confidence interval (CI): 7.60-10.02). The median OS of the patients diagnosed at the latter era was significantly better (11.1; 95% CI: 8.8-13.4 vs. 7.0; 95% CI: 5.7-8.3 months, <i>p</i> ≤ 0.001). A total number of 524 (53.8%) patients received drug therapy. Altogether, TTs including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTORi), and vascular endothelial growth factor inhibitor covered 331 (63.2%) of first-line treatments, whereas interferon and its combinations with chemotherapy were used for 186 (35.5%) patients. The median OS rates for TT and interferon as first-line therapy groups were 19.9 (16.9-22.8) and 14.9 (12.3-17.4) months, respectively. The OS for patients who did not receive drug therapy after cytoreductive nephrectomy was dismal. We found that the OS estimate of mRCC patients in Finland has improved since the introduction of tyrosine kinase inhibitors. However, the prognosis remains poor for frail, elderly patients with an impaired performance status.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"5237695"},"PeriodicalIF":1.5,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39334829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Benefit of Intervention Treatment in Advanced Anaplastic Thyroid Cancer.","authors":"Pornthep Kasemsiri,&nbsp;Pimpika Chaisakgreenon,&nbsp;Patravoot Vatanasapt,&nbsp;Supawan Laohasiriwong,&nbsp;Watchareeporn Teeramatwanich,&nbsp;Cattleya Thongrong,&nbsp;Teeraporn Ratanaanekchai,&nbsp;Surapol Suetrong","doi":"10.1155/2021/5545127","DOIUrl":"https://doi.org/10.1155/2021/5545127","url":null,"abstract":"<p><strong>Background: </strong>The management of anaplastic thyroid cancer (ATC) is controversial; thus, proper treatment and prognostic factors should be investigated.</p><p><strong>Objectives: </strong>To compare the survival outcomes of the intervention and palliative treatment in ATC patients.</p><p><strong>Methods: </strong>A hospital-based retrospective study was conducted at a single tertiary university hospital. The medical record charts were retrieved from November 20, 1987, to December 31, 2016. The final follow-up ended by December 31, 2017. The patients' demographic data, laboratory data, clinical presentation, and treatment modality results were analyzed.</p><p><strong>Results: </strong>One hundred twenty-one records were analyzed with a one-year overall survival rate of 3.5% (median survival time: 77 days); however, 16 cases had insufficient data to classify staging and treatment modalities. Therefore, 105 ATC patients (37 with stage IVa, 39 with stage IVb, and 29 with stage IVc disease) were included with a one-year overall survival rate of 4.0% (median survival time of 82 days). Intervention treatment allowed longer median survival times (<i>p</i> < 0.05) and a better survival rate (<i>p</i> < 0.05). Among the interventional treatment groups, postoperative chemoradiation yielded the longest median survival time (187 days) and the highest survival rate (20%) (<i>p</i> < 0.05). The intervention modality allowed a better median survival time at all stages, particularly in stage IVa (<i>p</i> < 0.05). Unfavorable prognostic factors were adjusted for in a multiple Cox regression model showing that significant factors included age ≥65 years (hazard ratio HR: 2.57), palliative treatment (HR: 1.85), and leukocytosis ≥10,000 cells/mm³ (HR: 2.76).</p><p><strong>Conclusions: </strong>Intervention treatment provided a better survival outcome in all stages, particularly in stage IVa, with a significantly better median survival time. Among interventional treatments, postoperative chemoradiation led to the longest survival rate, suggesting that this treatment should be considered in ATC patients with resectable tumors and no poor prognostic factors, such as older age and leukocytosis.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"5545127"},"PeriodicalIF":1.5,"publicationDate":"2021-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39010749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.","authors":"Yogi Prabowo,&nbsp;Iwan Setiawan,&nbsp;Achmad Fauzi Kamal,&nbsp;Evelina Kodrat,&nbsp;Muhammad Luqman Labib Zufar","doi":"10.1155/2021/8843325","DOIUrl":"https://doi.org/10.1155/2021/8843325","url":null,"abstract":"Background Multimodality treatment, incorporating neoadjuvant chemotherapy and adjuvant chemotherapy, is the standard management plan for osteosarcoma that increases the overall survival (OS) rate. However, data regarding prognostic factors affecting the histopathological response following neoadjuvant chemotherapy is limited. Patients and Methods. We retrospectively reviewed patients diagnosed with osteosarcoma in our center between 2008 and 2018. We classified patient characteristics according to gender, age, tumor size, site and stage at diagnosis, site of metastasis, type of surgery, necrosis rate based on the Huvos grading system, and the number of neoadjuvant chemotherapy cycles. We divided response to neoadjuvant chemotherapy into poor responder for patients with Huvos grades 1 and 2 and good responder for patients with Huvos grades 3 and 4. We also documented patients' survival and follow-up information. Results We reviewed 64 patients within 5–65 years of age, dominated by men (62.5%). The distal femur (53.1%) was the most common site of osteosarcoma. Fifteen (23.4%) patients had a good response while 49 (76.6%) patients were poor responders to neoadjuvant chemotherapy based on the Huvos grading system. Based on multivariate analysis, gender (p = 0.012), age (p = 0.029), symptom duration (p = 0.004), and tumor enlargement after neoadjuvant chemotherapy (p < 0.001) were significantly associated with histopathological response. A scoring system was proposed integrating these significant variables (age > 20 years = 1 point, female gender = 1 point, symptom duration > 12 weeks = 1 point, and increased tumor size after neoadjuvant chemotherapy = 2 points). This scoring system divides patients into two groups with a total score of more than two predicting a poor responder to neoadjuvant chemotherapy. Conclusions Age, gender, symptoms duration, and tumor size after neoadjuvant chemotherapy are the prognostic features that affect the histopathological response to neoadjuvant chemotherapy in patients with osteosarcoma.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"8843325"},"PeriodicalIF":1.5,"publicationDate":"2021-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38988624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Experience in Peritoneal Carcinomatosis: Single-Center Analysis of 180 Cases.","authors":"Kursat Karadayi,&nbsp;Meric Emre Bostanci,&nbsp;Murat Can Mollaoglu,&nbsp;Ufuk Karabacak","doi":"10.1155/2021/8851751","DOIUrl":"https://doi.org/10.1155/2021/8851751","url":null,"abstract":"<p><strong>Background: </strong>In peritoneal carcinomatosis (PC), increased life span and disease-free survival times are shown in patients with hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (SRC). In this study, our main objective was to present our experience of performing SRC and perioperative intraperitoneal chemotherapy (HIPEC and EPIC) on patients with PC, in light of the literature.</p><p><strong>Methods: </strong>Demographic data, follow-up results, peritoneal carcinomatosis index (PCI), completeness of cytoreduction (CCR) score, and morbidity and mortality rates of 180 patients treated with SRC + HIPEC + EPIC for PC at the Department of Surgical Oncology at Sivas Cumhuriyet University between January 2008 and July 2020 were analyzed retrospectively.</p><p><strong>Results: </strong>Distribution of 180 PC cases according to primary organs included 53 ovarian, 39 colorectal, 33 stomach, 25 primary peritoneum, 10 uterus, 10 tuba, five soft tissue, and five appendix originated carcinoma. The average PCI of the cases detected preoperatively was 21 (5-30). Completeness of cytoreduction scores of CCR-0 in 102 cases, CCR-1 in 67 cases, CCR-2 in eight cases, and CCR-3 in three cases was obtained. Median operation time was 300 (200-540) minutes. Perioperative morbidity rate was 47.0%, and perioperative mortality rate was 13.5%.</p><p><strong>Conclusion: </strong>The peritonectomy procedure is a difficult, long-lasting, troublesome intervention, but it is the most important treatment option with acceptable morbidity and mortality rates in patients selected for PC treatment in experienced centers.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"8851751"},"PeriodicalIF":1.5,"publicationDate":"2021-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38890298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of IORT (Radical and Boost Dose) and EBRT in Terms of Disease-Free Survival and Overall Survival according to Demographic, Pathologic, and Biological Factors in Patients with Breast Cancer.","authors":"Solmaz Hashemi,&nbsp;Seyedmohammadreza Javadi,&nbsp;Mohammad Esmaeil Akbari,&nbsp;Hamidreza Mirzaei,&nbsp;Seied Rabi Mahdavi","doi":"10.1155/2021/2476527","DOIUrl":"https://doi.org/10.1155/2021/2476527","url":null,"abstract":"<p><strong>Background: </strong>The standard treatment for breast cancer is breast-conserving surgery (BCS) with radiotherapy. If external beam radiation therapy (EBRT) can be safely replaced with intraoperative radiotherapy (IORT), it will help patients to save their breast and to have equivocal or better results in DFS and overall survival (OS).</p><p><strong>Methods: </strong>A total of 2022 patients with breast cancer treated during 6 years were enrolled in the current study. A total of 657, 376, and 989 patients received EBRT, radical, and boost dose by IORT, respectively, according to the IRIORT consensus protocol. The primary endpoint was recurrence and death. The secondary endpoint was the role of variables in recurrence and death.</p><p><strong>Results: </strong>With a mean follow-up of 34.5 and 40.18 months for the IORT and EBRT groups, respectively, there was a significant difference in DFS between electron boost and X-ray boost groups (<i>P</i>=0.037) and the electron radical group compared with EBRT (<i>P</i>=0.025), but there was no significant difference between other boost and radical groups in DFS and OS.</p><p><strong>Conclusions: </strong>IORT can be a preferred treatment modality because of its noninferior outcomes, and in some special conditions, it has superior outcomes compared to EBRT, particularly in delivering radical dose with IORT.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"2476527"},"PeriodicalIF":1.5,"publicationDate":"2021-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38964000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Can a Multidisciplinary Approach Improve Prognosis of Soft-Tissue Sarcomas of Extremities?","authors":"Asmae Mazti,&nbsp;Mohamed El Idrissi,&nbsp;Abdelhalim El Ibrahimi,&nbsp;Mustapha El Maaroufi,&nbsp;Ghizlane El Koubaiti,&nbsp;Touria Bouhafa,&nbsp;Samira El Fakir,&nbsp;Samia Arifi,&nbsp;Abdelmajid Mrini,&nbsp;Laila Chbani","doi":"10.1155/2021/8871557","DOIUrl":"https://doi.org/10.1155/2021/8871557","url":null,"abstract":"<p><p>Soft-tissue sarcomas are malignant tumors that require good management within specialized centers. Our study aims to assess the benefit of handling these kinds of tumors using the Multidisciplinary Meeting (MDM) approach. The current paper details this approach through a prospective study that has lasted for 42 months in the HASSAN II University Hospital Center, Fez, Morocco. During this research work, 116 cases were selected with an average age of 53 years. In 95.7% of the cases, it was found that the lower limb was the most frequent tumor type (78.4%). Also, ninety-two (92) patients (79.3%) have had a prior biopsy. Ninety-nine (99) patients (85.3%) have received a magnetic resonance imaging scan (MRI) before surgery. Sixty-three (63) patients were operated on, including R0 resection used for 37 patients, R1 used for 21 patients, and R2 used for five patients. As a result, liposarcomas were the most frequent type (30.1%), followed by synovial sarcomas (14.6%), leiomyosarcomas (9.5%), ewing sarcoma (8.6), and undifferentiated pleomorphic sarcomas (7.7%). In addition, neoadjuvant chemotherapy was used for 36 patients. The other 22 patients received adjuvant chemotherapy and/or radiotherapy. The overall survival rate was 60.56 months, which proves a significant improvement, thanks to the multidisciplinary meeting approach. <i>Conclusion</i>. The conducted investigation has shown that using MDM for managing soft-tissue sarcomas of extremities improves the patients' survival rate. Moreover, results have proven MDM might allow optimal treatment regarding less local recurrence and metastasis.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"8871557"},"PeriodicalIF":1.5,"publicationDate":"2021-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25573333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Diagnosis to Management; Mucocele of Stump Appendicitis, Extremely Rare Finding in an Uncommon Surgical Disease: Literature Review.","authors":"Syed Muhammad Ali,&nbsp;Mohannad Al-Tarakji,&nbsp;Fakhar Shahid,&nbsp;Amjad Salah Qabani,&nbsp;Amjad Ali Shah,&nbsp;Khalid Ahmed,&nbsp;Muhammad Burhan Khan,&nbsp;Inamullah","doi":"10.1155/2021/8816643","DOIUrl":"https://doi.org/10.1155/2021/8816643","url":null,"abstract":"<p><p>Mucocele of the appendix is the accumulation of mucoid material in the appendiceal lumen. Although the terminology is imprecise, as it does not differentiate between the benign and malignant nature of the condition, preoperative recognition is imperative as spillage of the mucus during surgical handling can result in grave complications like pseudomyxoma peritonei. Mucocele developing in a stump of the appendix, i.e., a remnant of appendiceal tissue after surgical removal of an inflamed organ, is an extremely uncommon phenomenon, as not many cases are reported in the literature. In this review, all cases reported in English literature are discussed.</p>","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"8816643"},"PeriodicalIF":1.5,"publicationDate":"2021-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25402761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopic versus Open Complete Mesocolic Excision for Right Colon Cancer.","authors":"Ali Zedan,&nbsp;Essam Elshiekh,&nbsp;Mohamed I Omar,&nbsp;Mohamad Raafat,&nbsp;Salah M Khallaf,&nbsp;Haisam Atta,&nbsp;Marwa T Hussien","doi":"10.1155/2021/8859879","DOIUrl":"https://doi.org/10.1155/2021/8859879","url":null,"abstract":"Results The mean operative time was significantly longer in the LCME group than that in the OCME group with less mean intraoperative blood loss. Conversion was required in 4 patients (8.3%) in the LCME group. The use of laparoscopy increased the number of harvested lymph nodes compared to the open approach (39.81 ± 16.74 vs. 32.65 ± 12.28, respectively, P=0.010). The laparoscopic approach was associated with a shorter time interval to first flatus as well as shorter time interval to liquid and normal diet after surgery. The postoperative hospital stay was significantly shorter in the LCME group. The complication rate was slightly lower in the LCME (14.7%) than in the OCME group (27.2%) (P=0.252). The 3-year OS in the LCME group was similar to that in OCME (78.2% vs. 63.2%, respectively, P value = 0.423). The three-year DFS in the laparoscopic group was higher (74.5%) than the open group (60.0%), but did not reach statistical significance (P value = 0.266). Conclusions In conclusion, laparoscopic CME right hemicolectomy is a technically feasible and safe procedure if surgeon expertise is present. LCME has long-term oncologic outcomes (recurrence and survival) comparable to open surgery for management of patients with stage II or III colon cancer.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2021 ","pages":"8859879"},"PeriodicalIF":1.5,"publicationDate":"2021-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25383279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}